Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Esserman

Showing results (81-90 of 143) with videos related to

Pageof 15
Sort By:
Annals of Surgical Oncology|August 5, 2005
The effect of sentinel node tumor burden on non-sentinel node status and recurrence rates in breast cancerYang-Guo Fan, Yah-Yuen Tan, Chen-Teng Wu, et al.
JMIR Cancer|February 25, 2022
Evaluation of the Pathways for Survivors Program to Address Breast Cancer Survivorship-Associated Distress: Survey StudySaumya Umashankar, Matina Elise Mamounas, Madeline Matthys, et al.
The Lancet. Oncology|June 2, 2012
A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpointsDebora Fumagalli, Philippe L Bedard, Zeina Nahleh, et al.
Breast Cancer Research and Treatment|October 28, 2016
Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breastMichael J Campbell, Frederick Baehner, Tess O'Meara, et al.
Genome Biology|November 22, 2007
Analysis of molecular inversion probe performance for allele copy number determinationYuker Wang, Martin Moorhead, George Karlin-Neumann, et al.
JAMIA Open|June 7, 2021
PRoBE the cloud toolkit: finding the best biomarkers of drug response within a breast cancer clinical trialNicholas O'Grady, David L Gibbs, Kawther Abdilleh, et al.
CHEST Critical Care|June 4, 2025
Anti-CD14 treatment in patients with severe COVID-19: Clinical and biological effects in a Phase 2 randomized open-label adaptive platform clinical trialF Linzee Mabrey, Thomas R Martin, Carolyn S Calfee, et al.
Communications Medicine|March 30, 2023
Radiomic tumor phenotypes augment molecular profiling in predicting recurrence free survival after breast neoadjuvant chemotherapyRhea Chitalia, Marios Miliotis, Nariman Jahani, et al.
Critical Care (London, England)|February 21, 2024
Novel subtypes of severe COVID-19 respiratory failure based on biological heterogeneity: a secondary analysis of a randomized controlled trialNarges Alipanah-Lechner, James Hurst-Hopf, Kevin Delucchi, et al.
JAMA|August 5, 2024
Modernizing the Data Infrastructure for Clinical Research to Meet Evolving Demands for EvidenceJoseph B Franklin, Caroline Marra, Kaleab Z Abebe, et al.
Pageof 15

Showing results (81-90 of 143) with videos related to

Sort By:
Pageof 15
Annals of Surgical Oncology|August 5, 2005
The effect of sentinel node tumor burden on non-sentinel node status and recurrence rates in breast cancerYang-Guo Fan, Yah-Yuen Tan, Chen-Teng Wu, et al.
JMIR Cancer|February 25, 2022
Evaluation of the Pathways for Survivors Program to Address Breast Cancer Survivorship-Associated Distress: Survey StudySaumya Umashankar, Matina Elise Mamounas, Madeline Matthys, et al.
The Lancet. Oncology|June 2, 2012
A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpointsDebora Fumagalli, Philippe L Bedard, Zeina Nahleh, et al.
Breast Cancer Research and Treatment|October 28, 2016
Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breastMichael J Campbell, Frederick Baehner, Tess O'Meara, et al.
Genome Biology|November 22, 2007
Analysis of molecular inversion probe performance for allele copy number determinationYuker Wang, Martin Moorhead, George Karlin-Neumann, et al.
JAMIA Open|June 7, 2021
PRoBE the cloud toolkit: finding the best biomarkers of drug response within a breast cancer clinical trialNicholas O'Grady, David L Gibbs, Kawther Abdilleh, et al.
CHEST Critical Care|June 4, 2025
Anti-CD14 treatment in patients with severe COVID-19: Clinical and biological effects in a Phase 2 randomized open-label adaptive platform clinical trialF Linzee Mabrey, Thomas R Martin, Carolyn S Calfee, et al.
Communications Medicine|March 30, 2023
Radiomic tumor phenotypes augment molecular profiling in predicting recurrence free survival after breast neoadjuvant chemotherapyRhea Chitalia, Marios Miliotis, Nariman Jahani, et al.
Critical Care (London, England)|February 21, 2024
Novel subtypes of severe COVID-19 respiratory failure based on biological heterogeneity: a secondary analysis of a randomized controlled trialNarges Alipanah-Lechner, James Hurst-Hopf, Kevin Delucchi, et al.
JAMA|August 5, 2024
Modernizing the Data Infrastructure for Clinical Research to Meet Evolving Demands for EvidenceJoseph B Franklin, Caroline Marra, Kaleab Z Abebe, et al.
Pageof 15